Prix Sunshine Lake Pharma Co., Ltd. (06887.HK)

Sunshine Lake Pharma Co., Ltd. operates as a pharmaceutical company. The company is headquartered in Dongguan, Guangdong and currently employs 6,533 full-time employees. The company went IPO on 2025-08-07. The firm focuses on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars. The Company’s anti-infective products include Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride. The Company’s commercialized chronic disease treatment drugs primarily focus on the treatment of diabetes, hyperuricemia, hypertension and stomach acid related disease, including insulin products and generic drugs. The firm also focuses on therapeutic area of oncology.